ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $639,694 | -53.6% | 93,386 | -29.8% | 0.00% | -50.0% |
| Q2 2023 | $1,379,583 | +304.1% | 133,036 | +215.3% | 0.00% | +300.0% |
| Q1 2023 | $341,398 | +126.1% | 42,200 | -54.9% | 0.00% | 0.0% |
| Q2 2020 | $151,000 | +55.7% | 93,518 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $97,000 | -96.0% | 93,518 | -92.8% | 0.00% | -87.5% |
| Q4 2019 | $2,449,000 | -39.3% | 1,295,966 | -65.3% | 0.01% | -46.7% |
| Q3 2019 | $4,034,000 | -10.5% | 3,734,793 | +81.5% | 0.02% | -6.2% |
| Q2 2019 | $4,507,000 | -36.5% | 2,057,936 | +73.6% | 0.02% | -40.7% |
| Q1 2019 | $7,101,000 | +44.2% | 1,185,528 | +77.9% | 0.03% | +22.7% |
| Q4 2018 | $4,925,000 | -15.8% | 666,430 | +65.5% | 0.02% | +4.8% |
| Q3 2018 | $5,846,000 | +260.6% | 402,624 | +396.1% | 0.02% | +200.0% |
| Q2 2018 | $1,621,000 | – | 81,166 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
| COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
| Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
| VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
| Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
| Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
| Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
| Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
| Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |